ADVANCED COMPREHENSIVE MAGNETIC RESONANCE SOLUTION FOR THE NONINVASIVE CHARACTERIZATION OF HIGH RESOLUTION METABOLIC BIOMARKERS OF RISK IN PATIENTS WITH ALZHEIMER'S DISEASE AND DEMENTIA

NIH SBIR快速通道，PAS-22-196用于非侵入性表征的高级综合磁共振解决方案 阿尔茨海默病和痴呆症患者高分辨率代谢生物标志物风险研究 项目摘要 该项目致力于阿尔茨海默病（AD）和AD相关痴呆症的研究进展 （ADRD）国家老龄问题研究所倡议（PAS-22-196）。我们建议开发一种先进的 硬件-软件包ADRD 360，用于最佳采集、处理和分析磁共振 核磁共振成像（MRI）和波谱（MRS）。ADRD 360将有助于定位代谢 签名，并以比目前可能的更高的分辨率获得MRI和MRS脑部数据。 临床MR系统。高分辨率MRI和MRS将在早期诊断中发挥至关重要的作用。 预测发展AD的风险。ADRD 360可能导致早期发现结构性和 代谢参数作为AD、ADRD、其他 神经障碍和精神疾病。该项目将提供完整的解决方案， 开发和优化1）接近最终固有的先进射频（RF）线圈 信噪比（UISNR）和可接受的比吸收率（SAR）; 2）推动结构MR 成像分辨率超过商业设备; 3）推进匀场程序，以改善 B 0场的均匀性; 4）允许高分辨率、多维、多体积MRS检查 在合理的扫描时间内具有100%的结构-功能相关性; 5）独立的，易于使用的程序 它提供了多维结构和多体积MRS采集之间的关键联系， 包括通过有效处理苛刻的光谱处理来进行临床和代谢解释 和分析需求;以及6）全面的MRI-MRS度量系统校准、质量保证和 确认体模对于确认测量的再现性至关重要。首先，我们将演示 通过确定结构和代谢MRI-MRS参数的研究效用和临床适用性 在健康受试者中传播。本研究的结果对于受试者的解释至关重要， 发展AD的风险更高。这项工作建立在我们的专业知识，创造了第一个商业双- 调谐1H-31 P 1.5T和3 T头部线圈（R44 NS 037273）。这项研究也建立在我们的工作与 开发自动B 0匀场程序（FWHM 11.7 ± 1.9 Hz，n=94，1.5T）， 交互式MRS软件。该项目将提供“早期AD检测的完整解决方案”， 在高分辨率结构和功能MRI检查中进行高级脑部MR评估，以及 基于多核代谢的MRS采集。我们的授权西门子供应商协议将推动 ADRD 360的开发和商业化。我们的目标是让研究人员满意， 3 T和7 T MR系统的最终固有SNR 31 P和1H限值。我们计划展示 通过识别关键的结构和代谢MR脑参数， 作为筛选生物标志物在人类轻度认知障碍由于老化，AD，和相关的痴呆症。 机密专有信息高级成像研究dba SREE医疗系统

NIH SBIR Fast-Track, PAS-22-196 Advanced Comprehensive Magnetic Resonance Solution for the Non Invasive Characterization of No Clinical Trials High Resolution Metabolic Biomarkers of Risk in Patients with Alzheimer’s Disease and Dementia Project Summary This project addresses the Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Initiative of the National Institute on Aging (PAS-22-196). We propose to develop an advanced hardware-software package, ADRD360, to optimally acquire, process, and analyze magnetic resonance imaging (MRI) and spectroscopy (MRS) in the human brain. The ADRD360 will help to localize metabolic signatures and obtain MRI and MRS brain data at much higher resolutions than currently possible on clinical MR systems. Highly resolved MRI and MRS will be of utmost importance to aid in the early prediction of the risk of developing AD. The ADRD360 may lead to the early detection of structural and metabolic parameters as predictive diagnostic tool biomarkers in patients with AD, ADRD, other neurological disorders and psychiatric diseases. This project will offer a complete solution with the development and optimization of 1) advanced radio-frequency (RF) coils approaching ultimate intrinsic signal-to-noises (UISNRs) and acceptable specific absorption rates (SARs); 2) pushing structural MR imaging resolutions over commercial devices; 3) advancing shimming procedures to improve the homogeneity of the B0 field; 4) permitting high-resolution, multi-dimensional, multi-volume MRS exams with 100% structure-function correlation in reasonable scan times; 5) a stand-alone, easy-to-use program that provides the crucial link between multi-dimensional structural and multi-volume MRS acquisition, including its clinical and metabolic interpretation by effectively tackling the demanding spectral processing and analysis needs; and 6) a comprehensive MRI-MRS metrics system calibration, quality assurance and validation phantom essential to confirm reproducibility of measurements. Initially, we will demonstrate the research utility and clinical applicability by determining the structural and metabolic MRI-MRS parameter spread in healthy subjects. Results from this study will become essential to interpretation in subjects at higher risk of developing AD. This work builds upon our expertise in creating the first commercial dual- tuned 1H-31P 1.5T and 3T head coils (R44NS037273). This research also builds upon our work with the development of an automated B0 shimming program (FWHM 11.7 ± 1.9 Hz, n=94 at 1.5T) and the interactive MRS software. This project will offer 'A Complete Solution for the Early AD Detection’ with advanced brain MR assessments in the high-resolution structural and functional MRI exams, and multinuclear metabolic-based MRS acquisitions. Our licensed Siemens vendor agreement will propel the development and commercialization of the ADRD360. We aim to satiate the researchers by approaching the ultimate intrinsic SNR 31P and 1H limits on the 3T and 7T MR systems. We plan to demonstrate the clinical advantages by identifying critical structural and metabolic MR brain parameters that can be used as screening biomarkers in humans with mild cognitive impairment due to aging, AD, and related dementia. Confidential Proprietary Information Advanced Imaging Research dba SREE Medical Systems